Consolidated Financial Results for the Three Months Ended October 31, 2025 FY26 Ending July - Q1 (Aug-Oct) Supplementary Materials
December 11, 2025
Pharma Foods International Co., Ltd.
Note : This document has been translated from the Japanese original for reference purposes only. In the event of any
discrepancy between this translated document and the Japanese original, the original shall prevail.
FY26 Ending July - Q1 (Aug-Oct) Financial Results
- Initiatives of the "New Value Creation 1K Project"
FY26 Q1 Financial Results Highlights
Q1 consolidated net sales increased 7.6% YoY, driven by 9.5% growth in the BtoC business.
Advertising expenses of 11,434 million yen were recorded as planned to develop new
revenue pillars. The full-year forecast remains unchanged.
(Million Yen)
FY26 Q1
FY25 Q1
Change
%
Net Sales
15,712
14,596
1,115
7.6%
Advertising Expenses
11,434
7,943
3,490
43.9%
Operating Profit
△2,511
882
△3,393
ー
Ordinary Profit
△2,644
888
△3,532
ー
Net Income Attributable to
Parent
△1,891
360
△2,251
ー
(Yen)
FY26 Q1
FY25 Q1
Change
%
EPS
△65.52
12.86
△78.38
ー
Operating Profit Change Factors by Segment - FY26 Q1Advertising investment reached its second-highest quarterly level on record, focusing on
new products expected to become future revenue pillars.
882
△235
△2,944
(Unit: Million Yen)
FY25 Q1 (A)
BtoB
△40 △172
BtoC
Biomedical Others*1
△2,511
FY26 Q1
Adjustments*2
Operating Profit by Segment - FY26 Q1
BtoB BtoC
Biomedical
Others*1 /
Adjustments*2
FY26 Q1 Consolidated Operating Profit
△664
△2,511
(Unit: Million Yen )
△1,836
△137
+128
In-store distribution of own-brand products is progressing well.
Strategic investment in the
strong-performing "Newmo V" and "LACTRON Tablets"
Advancing drug discovery research in the oncology field.
SG&A expenses related to Group operations
Active advertising investment (11,434 million yen), centered on "Newmo V" and "LACTRON Tablets," to foster new revenue pillars.